467 related articles for article (PubMed ID: 25510418)
21. Mucopolysaccharidoses I and II: Brief Review of Therapeutic Options and Supportive/Palliative Therapies.
Nan H; Park C; Maeng S
Biomed Res Int; 2020; 2020():2408402. PubMed ID: 33344633
[No Abstract] [Full Text] [Related]
22. Correction of murine mucopolysaccharidosis type IIIA central nervous system pathology by intracerebroventricular lentiviral-mediated gene delivery.
McIntyre C; Derrick-Roberts AL; Byers S; Anson DS
J Gene Med; 2014; 16(11-12):374-87. PubMed ID: 25418946
[TBL] [Abstract][Full Text] [Related]
23. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery.
Fu H; Dirosario J; Killedar S; Zaraspe K; McCarty DM
Mol Ther; 2011 Jun; 19(6):1025-33. PubMed ID: 21386820
[TBL] [Abstract][Full Text] [Related]
24. Challenges in adeno-associated virus-based treatment of central nervous system diseases through systemic injection.
Huang L; Wan J; Wu Y; Tian Y; Yao Y; Yao S; Ji X; Wang S; Su Z; Xu H
Life Sci; 2021 Apr; 270():119142. PubMed ID: 33524419
[TBL] [Abstract][Full Text] [Related]
25. Possible strategies to cross the blood-brain barrier.
Bellettato CM; Scarpa M
Ital J Pediatr; 2018 Nov; 44(Suppl 2):131. PubMed ID: 30442184
[TBL] [Abstract][Full Text] [Related]
26. Design and applications of gene therapy vectors for mucopolysaccharidosis in Colombia.
Alméciga-Diaz CJ; Barrera LA
Gene Ther; 2020 Feb; 27(1-2):104-107. PubMed ID: 31267008
[TBL] [Abstract][Full Text] [Related]
27. Comparison of ventricular and intravenous lentiviral-mediated gene therapy for murine MPS VII.
Bielicki J; McIntyre C; Anson DS
Mol Genet Metab; 2010 Dec; 101(4):370-82. PubMed ID: 20864369
[TBL] [Abstract][Full Text] [Related]
28. [Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian F experts].
Giugliani R; Federhen A; Muñoz Rojas MV; Vieira TA; Artigalás O; Pinto LL; Azevedo AC; Acosta AX; Bomfim C; Lourenço CM; Kim CA; Horovitz D; Souza DB; Norato D; Marinho D; Palhares D; Santos ES; Ribeiro E; Valadares ER; Guarany F; De Lucca GR; Pimentel H; Souza IN; Corrêa Neto J; Fraga JC; Góes JE; Cabral JM; Simeonato J; Llerena JC; Jardim LB; Giuliani Lde R; Silva LC; Santos M; Moreira MA; Kerstenetzky M; Ribeiro M; Ruas N; Barrios P; Aranda P; Honjo R; Boy R; Costa R; Souza CF; Alcântara FF; Avilla SG; Fagondes S; Martins AM
Rev Assoc Med Bras (1992); 2010; 56(3):271-7. PubMed ID: 20676532
[TBL] [Abstract][Full Text] [Related]
29. Ex Vivo and In Vivo Gene Therapy for Mucopolysaccharidoses: State of the Art.
Consiglieri G; Bernardo ME; Brunetti-Pierri N; Aiuti A
Hematol Oncol Clin North Am; 2022 Aug; 36(4):865-878. PubMed ID: 35773049
[TBL] [Abstract][Full Text] [Related]
30. Restoration of central nervous system alpha-N-acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno-associated viral type 2 vector delivery.
Fu H; DiRosario J; Kang L; Muenzer J; McCarty DM
J Gene Med; 2010 Jul; 12(7):624-33. PubMed ID: 20603889
[TBL] [Abstract][Full Text] [Related]
31. Mucopolysaccharidoses and the eye.
Ashworth JL; Biswas S; Wraith E; Lloyd IC
Surv Ophthalmol; 2006; 51(1):1-17. PubMed ID: 16414358
[TBL] [Abstract][Full Text] [Related]
32. [Principles of therapeutic approaches for mucopolysaccharidoses].
Caillaud C
Arch Pediatr; 2014 Jun; 21 Suppl 1():S39-45. PubMed ID: 25063383
[TBL] [Abstract][Full Text] [Related]
33. Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future.
Chen HH; Sawamoto K; Mason RW; Kobayashi H; Yamaguchi S; Suzuki Y; Orii K; Orii T; Tomatsu S
J Hum Genet; 2019 Nov; 64(11):1153-1171. PubMed ID: 31455839
[TBL] [Abstract][Full Text] [Related]
34. Evading the AAV Immune Response in Mucopolysaccharidoses.
Piechnik M; Sawamoto K; Ohnishi H; Kawamoto N; Ago Y; Tomatsu S
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32414007
[TBL] [Abstract][Full Text] [Related]
35. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Evenstar LB; Kitto KF; Nan Z; Fairbanks CA; Low WC; Kozarsky KF; McIvor RS
Hum Gene Ther; 2017 Aug; 28(8):626-638. PubMed ID: 28478695
[TBL] [Abstract][Full Text] [Related]
36. Targeted enzyme delivery systems in lysosomal disorders: an innovative form of therapy for mucopolysaccharidosis.
Safary A; Akbarzadeh Khiavi M; Omidi Y; Rafi MA
Cell Mol Life Sci; 2019 Sep; 76(17):3363-3381. PubMed ID: 31101939
[TBL] [Abstract][Full Text] [Related]
37. Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice.
Watson G; Bastacky J; Belichenko P; Buddhikot M; Jungles S; Vellard M; Mobley WC; Kakkis E
Gene Ther; 2006 Jun; 13(11):917-25. PubMed ID: 16482204
[TBL] [Abstract][Full Text] [Related]
38. AAV gene delivery to the spinal cord: serotypes, methods, candidate diseases, and clinical trials.
Hardcastle N; Boulis NM; Federici T
Expert Opin Biol Ther; 2018 Mar; 18(3):293-307. PubMed ID: 29249183
[TBL] [Abstract][Full Text] [Related]
39. Gene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches.
Fraldi A; Serafini M; Sorrentino NC; Gentner B; Aiuti A; Bernardo ME
Ital J Pediatr; 2018 Nov; 44(Suppl 2):130. PubMed ID: 30442177
[TBL] [Abstract][Full Text] [Related]
40. Therapies for neurological disease in the mucopolysaccharidoses.
Anson DS; McIntyre C; Byers S
Curr Gene Ther; 2011 Apr; 11(2):132-43. PubMed ID: 21291356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
